M1415 HCPCS code: Patients who did not have a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy
M1415 is the HCPCS Level II code for patients who did not have a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case.
Code details
| Field | Value |
|---|---|
| Section | M codes — Medical services and quality measures |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 00 — Not separately priced by Medicare |
| BETOS category | Z2 |
| Added | 2025-01-01 |
| Last action effective | 2025-01-01 |
What changed for M1415
- 2025-01-01: M1415 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code M1415?
M1415 is the HCPCS Level II code for patients who did not have a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy. Short descriptor: "No pos pdl1 bef ici ther".
Does Medicare cover M1415?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related M14 codes
- M1400 — Patients who died during the follow-up period
- M1401 — Stages i-iii breast cancer
- M1402 — Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group
- M1403 — Patients with baseline and follow-up promis surveys documented in the medical record
- M1404 — Patients on a therapeutic clinical trial
- M1405 — Patients with recurrence/disease progression
- M1406 — Patients who leave the practice during the follow-up period
- M1407 — Patients who died during the follow-up period
- M1408 — Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
- M1409 — Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1410 — Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1411 — Currently on first-line immune checkpoint inhibitors without chemotherapy
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under M1415
- Watch M1415 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for M1415
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.